SBIR-STTR Award

Urine Protein Predictors of Nephrolithiasis
Award last edited on: 6/18/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$350,000
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
John R Asplin

Company Information

Litholink Corporation

2201 West Campbell Park Drive
Chicago, IL 60612
   (312) 243-0600
   bcoe@litholink.com
   www.litholink.com
Location: Single
Congr. District: 07
County: Cook

Phase I

Contract Number: 1R43DK070465-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2005
Phase I Amount
$100,000
The scientific and commercial objective of the proposed research is to improve the medical prevention of nephrolithiasis by developing a new clinical assay that can predict the recurrence of kidney stones in patients with this chronic and costly disease. Currently available technology, consisting of routine urine chemistry measurements, is a poor predictor of a patient's risk for developing recurrent stones. Those patients destined to recur would benefit from tests that could identify them in advance so that therapy or prevention could be implemented early. We have found three proteins that are known inhibitors of calcium oxalate crystal growth to be significantly altered in the urine of stone formers. Preliminary studies of family members of calcium stone formers have shown that measurements of these proteins combined with standard urine chemistry risk factors vastly improved the discrimination of stone formers from non stone formers compared to standard urine chemistries alone. Our hypothesis is that alterations in these proteins in the urine of kidney stone patients may serve as a marker of stone disease activity or vulnerability to recurrence. We propose to develop improved western blotting and ELISA methods to measure the most highly discriminating forms of these proteins. We will validate these assays by determining intraassay and interassay variability through multiple measurements of urine samples from a small set of stone forming and non stone forming men and women. We will also use these samples to evaluate the stability of the proteins under different storage conditions that approximate the way urine is currently collected and shipped to our laboratory. In Phase II, we will use these assays and conditions to prospectively test whether these protein measurements improve the identification of kidney stone patients compared to conventional urine chemistry stone risk factors in people within and outside of stone forming families, and in people with different types of stones

Phase II

Contract Number: 6R43DK070465-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2005
Phase II Amount
$250,000
The scientific and commercial objective of the proposed research is to improve the medical prevention of nephrolithiasis by developing a new clinical assay that can predict the recurrence of kidney stones in patients with this chronic and costly disease. Currently available technology, consisting of routine urine chemistry measurements, is a poor predictor of a patient's risk for developing recurrent stones. Those patients destined to recur would benefit from tests that could identify them in advance so that therapy or prevention could be implemented early. We have found three proteins that are known inhibitors of calcium oxalate crystal growth to be significantly altered in the urine of stone formers. Preliminary studies of family members of calcium stone formers have shown that measurements of these proteins combined with standard urine chemistry risk factors vastly improved the discrimination of stone formers from non stone formers compared to standard urine chemistries alone. Our hypothesis is that alterations in these proteins in the urine of kidney stone patients may serve as a marker of stone disease activity or vulnerability to recurrence. We propose to develop improved western blotting and ELISA methods to measure the most highly discriminating forms of these proteins. We will validate these assays by determining intraassay and interassay variability through multiple measurements of urine samples from a small set of stone forming and non stone forming men and women. We will also use these samples to evaluate the stability of the proteins under different storage conditions that approximate the way urine is currently collected and shipped to our laboratory. In Phase II, we will use these assays and conditions to prospectively test whether these protein measurements improve the identification of kidney stone patients compared to conventional urine chemistry stone risk factors in people within and outside of stone forming families, and in people with different types of stones.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Biomarker, Diagnosis Design /Evaluation, Disease /Disorder Proneness /Risk, Early Diagnosis, Nephrolithiasis, Proteinuria, Urinalysis Relapse /Recurrence, Technology /Technique Development, Urinary Tract Disorder Diagnosis Clinical Research, Enzyme Linked Immunosorbent Assay, Human Subject, Patient Oriented Research, Western Blotting